Key Highlights

  • Regeneron Pharmaceuticals (Nasdaq: REGN) dosed its first patient in the Phase 2 THIO-101 trial, noted September 16, 2026.
  • The trial is evaluating ateganosine in non-small cell lung cancer.
  • Part C of the Phase 2 expansion trial, pairing ateganosine with cemiplimab in third-line advanced NSCLC, showed an interim disease control rate of 90.5%.
  • Regeneron Pharmaceuticals (Nasdaq: REGN) trades near $779.74, up 0.66% on the day, with a market Capitalization of $80.28 billion.

First Patient Dosed in THIO-101

Regeneron Pharmaceuticals (Nasdaq: REGN) dosed its first patient in the Phase 2 THIO-101 trial evaluating ateganosine in non-small cell lung cancer, a milestone noted on September 16, 2026.

Strong Interim Data From Expansion Cohort

The update follows earlier positive initial efficacy data from Part C of the Phase 2 expansion trial, which evaluated ateganosine followed by cemiplimab in third-line advanced NSCLC. That cohort showed an interim disease control rate of 90.5%, data that had been noted on July 8, 2026, and which continue to inform the broader THIO-101 program at Regeneron Pharmaceuticals (Nasdaq: REGN).

Shares Steady

Regeneron Pharmaceuticals (Nasdaq: REGN) shares traded at $779.74, up $5.13, or 0.66%, giving the company a market capitalization of $80.28 billion as the ateganosine program advances through its Phase 2 development.

What is ateganosine?

Also known as THIO-101, it is a Regeneron candidate being evaluated in non-small cell lung cancer, including in combination with cemiplimab.

What did the Part C expansion data show?

An interim disease control rate of 90.5% in third-line advanced NSCLC patients treated with ateganosine followed by cemiplimab.

When did Regeneron dose its first Phase 2 THIO-101 patient?

The milestone was noted on September 16, 2026.